The human safety profile of DSIP is poorly characterized. Older, small studies generally described it as well tolerated, but that reassurance rests on thin, dated evidence rather than modern safety monitoring.[1][2]
Reviewed for accuracy · Last reviewed July 8, 2026Because DSIP is not FDA-approved and has not been studied in large modern trials, rarer or longer-term risks are simply not well documented. As an injectable peptide it carries the usual injection-site risks, and any product quality issues would fall outside a regulated supply chain.
There is no established management guidance for DSIP side effects because the human data are so limited. Anyone considering it should treat the safety picture as unknown and discuss it with a doctor first.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.